 Summary of study Consenting patients with ABC inoperable, locally advanced, recurrent or metastatic will receive CisGem chemotherapy and either cediranib experimental arm or placebo standard arm orally. Treatment will continue until disease progression chemotherapy will stop at 24 weeks with tumour reassessment by CTMRI scans at 12-weekly intervals. All patients will be followed up for survival analysis. 